Works (4)

Updated: July 5th, 2023 15:53

1992 journal article

QUANTITATIVE ESTIMATION OF THE THERMAL DOSE-MODIFYING FACTOR FOR CIS-DIAMMINEDICHLOROPLATINUM (CDDP) IN TUMOR-BEARING DOGS

INTERNATIONAL JOURNAL OF HYPERTHERMIA, 8(6), 761–769.

By: R. Page n, D. Thrall*, S. George, G. Price, G. Heidner*, M. Mcentee*, C. Novotney, M. Hauck*, M. Dewhirst*

MeSH headings : Animals; Bone Marrow / drug effects; Combined Modality Therapy; Dog Diseases / drug therapy; Dog Diseases / therapy; Dogs; Drug Tolerance; Female; Hyperthermia, Induced / methods; Hyperthermia, Induced / veterinary; Kidney / drug effects; Male; Neoplasms / drug therapy; Neoplasms / therapy; Neoplasms / veterinary; Organoplatinum Compounds / administration & dosage; Organoplatinum Compounds / adverse effects
TL;DR: A statistical method for estimating clinical toxicity was used to determine a theoretical isoeffect dose-modifying factor for dogs with disseminated or refractory neoplasia treated with cis-diammine dichloroplatinum (II) plus whole-body hyperthermia or CDDP alone. (via Semantic Scholar)
UN Sustainable Development Goal Categories
3. Good Health and Well-being (Web of Science; OpenAlex)
Source: Web Of Science
Added: August 6, 2018

1991 journal article

ANALYSIS OF SURVIVAL IN A RETROSPECTIVE STUDY OF 86 DOGS WITH BRAIN-TUMORS

JOURNAL OF VETERINARY INTERNAL MEDICINE, 5(4), 219–226.

By: G. Heidner n, J. Kornegay, R. Page, R. Dodge & D. Thrall

MeSH headings : Animals; Astrocytoma / mortality; Astrocytoma / therapy; Astrocytoma / veterinary; Brain Neoplasms / mortality; Brain Neoplasms / therapy; Brain Neoplasms / veterinary; Breeding; Choroid Plexus Neoplasms / mortality; Choroid Plexus Neoplasms / therapy; Choroid Plexus Neoplasms / veterinary; Dog Diseases / mortality; Dog Diseases / therapy; Dogs; Female; Follow-Up Studies; Male; Meningioma / mortality; Meningioma / therapy; Meningioma / veterinary; Prognosis; Retrospective Studies; Treatment Outcome
TL;DR: Both the mild and moderate groups had a more favorable prognosis compared with dogs who had severe initial neurologic impairment, and those dogs who were treated with cobalt-60 radiation, with or without other combinations of therapy, lived significantly longer than those who received surgery, or dogs who received symptomatic treatment. (via Semantic Scholar)
Source: Web Of Science
Added: August 6, 2018

1991 journal article

TREATMENT OF CANINE APPENDICULAR OSTEOSARCOMA USING CO-60 RADIATION AND INTRAARTERIAL CISPLATIN

JOURNAL OF VETERINARY INTERNAL MEDICINE, 5(6), 313–316.

By: G. Heidner*, R. Page n, M. Mcentee n, R. Dodge* & D. Thrall

MeSH headings : Animals; Bone Neoplasms / drug therapy; Bone Neoplasms / radiotherapy; Bone Neoplasms / veterinary; Chemotherapy, Adjuvant / veterinary; Cisplatin / administration & dosage; Cisplatin / therapeutic use; Cobalt Radioisotopes / therapeutic use; Dog Diseases / drug therapy; Dog Diseases / radiotherapy; Dog Diseases / therapy; Dogs; Extremities; Female; Infusion Pumps / veterinary; Infusions, Intra-Arterial / veterinary; Male; Osteosarcoma / drug therapy; Osteosarcoma / radiotherapy; Osteosarcoma / veterinary; Treatment Outcome
TL;DR: This mode of therapy was well tolerated and may be considered an alternative to amputation or limb-sparing surgical procedures in selected dogs with appendicular osteosarcoma. (via Semantic Scholar)
Source: Web Of Science
Added: August 6, 2018

1989 conference paper

Effect of temperature on cisplatin (CDDP) and carboplatin (CBDCA) pharmacokinetic disposition in dogs

Conference Proceedings, 2, 499–501.

By: R. Page, J. Riviere, G. Heidner, M. McEntee & D. Thrall

Source: NC State University Libraries
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2024) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.